Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether high dose statin therapy in patients with
aspirin mono antiplatelet therapy who had received drug-eluting stent (DES) previously and
were free of the adverse cardiac events during the first 12 months could be superior over
pravastatin therapy in the prevention of late adverse cardiac and cerebrovascular events
during the additional 12 months.
Study Design.